Similar articles for PMID: 29419479

Year	Number of Results
2003	1
2004	1
2005	1
2010	1
2011	1
2015	9
2016	20
2017	26
2018	30
2019	23
2020	16
2021	12
2022	3
2023	2
2024	0

1

The Effect of Total Tumor Volume on the Biologically Effective Dose to Tumor and Kidneys for ¹⁷⁷Lu-Labeled PSMA Peptides.

Begum NJ, Thieme A, Eberhardt N, Tauber R, D'Alessandria C, Beer AJ, Glatting G, Eiber M, Kletting P. Begum NJ, et al. J Nucl Med. 2018 Jun;59(6):929-933. doi: 10.2967/jnumed.117.203505. Epub 2018 Feb 1. J Nucl Med. 2018. PMID: 29419479 Free article.

2

Investigating the Effect of Ligand Amount and Injected Therapeutic Activity: A Simulation Study for 177Lu-Labeled PSMA-Targeting Peptides.

Kletting P, Schuchardt C, Kulkarni HR, Shahinfar M, Singh A, Glatting G, Baum RP, Beer AJ. Kletting P, et al. PLoS One. 2016 Sep 9;11(9):e0162303. doi: 10.1371/journal.pone.0162303. eCollection 2016. PLoS One. 2016. PMID: 27611841 Free PMC article.

3

Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer.

Delker A, Fendler WP, Kratochwil C, Brunegraf A, Gosewisch A, Gildehaus FJ, Tritschler S, Stief CG, Kopka K, Haberkorn U, Bartenstein P, Böning G. Delker A, et al. Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):42-51. doi: 10.1007/s00259-015-3174-7. Epub 2015 Aug 29. Eur J Nucl Med Mol Imaging. 2016. PMID: 26318602

4

Modeling and Predicting Tumor Response in Radioligand Therapy.

Kletting P, Thieme A, Eberhardt N, Rinscheid A, D'Alessandria C, Allmann J, Wester HJ, Tauber R, Beer AJ, Glatting G, Eiber M. Kletting P, et al. J Nucl Med. 2019 Jan;60(1):65-70. doi: 10.2967/jnumed.118.210377. Epub 2018 May 10. J Nucl Med. 2019. PMID: 29748236 Free article.

5

Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer.

Yadav MP, Ballal S, Tripathi M, Damle NA, Sahoo RK, Seth A, Bal C. Yadav MP, et al. Nucl Med Commun. 2017 Jan;38(1):91-98. doi: 10.1097/MNM.0000000000000606. Nucl Med Commun. 2017. PMID: 27782913

6

The ⁶⁸Ga/¹⁷⁷Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUV_max values and absorbed dose estimates.

Scarpa L, Buxbaum S, Kendler D, Fink K, Bektic J, Gruber L, Decristoforo C, Uprimny C, Lukas P, Horninger W, Virgolini I. Scarpa L, et al. Eur J Nucl Med Mol Imaging. 2017 May;44(5):788-800. doi: 10.1007/s00259-016-3609-9. Epub 2017 Jan 12. Eur J Nucl Med Mol Imaging. 2017. PMID: 28083690 Clinical Trial.

7

Third-line treatment and ¹⁷⁷Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review.

von Eyben FE, Roviello G, Kiljunen T, Uprimny C, Virgolini I, Kairemo K, Joensuu T. von Eyben FE, et al. Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):496-508. doi: 10.1007/s00259-017-3895-x. Epub 2017 Dec 16. Eur J Nucl Med Mol Imaging. 2018. PMID: 29247284 Free PMC article. Review.

8

Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer.

Kabasakal L, AbuQbeitah M, Aygün A, Yeyin N, Ocak M, Demirci E, Toklu T. Kabasakal L, et al. Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):1976-83. doi: 10.1007/s00259-015-3125-3. Epub 2015 Jul 31. Eur J Nucl Med Mol Imaging. 2015. PMID: 26227531

9

Systemic Radioligand Therapy with (177)Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer.

Heck MM, Retz M, D'Alessandria C, Rauscher I, Scheidhauer K, Maurer T, Storz E, Janssen F, Schottelius M, Wester HJ, Gschwend JE, Schwaiger M, Tauber R, Eiber M. Heck MM, et al. J Urol. 2016 Aug;196(2):382-91. doi: 10.1016/j.juro.2016.02.2969. Epub 2016 Mar 8. J Urol. 2016. PMID: 26964917

10

Radiation Dosimetry for ¹⁷⁷Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions.

Okamoto S, Thieme A, Allmann J, D'Alessandria C, Maurer T, Retz M, Tauber R, Heck MM, Wester HJ, Tamaki N, Fendler WP, Herrmann K, Pfob CH, Scheidhauer K, Schwaiger M, Ziegler S, Eiber M. Okamoto S, et al. J Nucl Med. 2017 Mar;58(3):445-450. doi: 10.2967/jnumed.116.178483. Epub 2016 Sep 22. J Nucl Med. 2017. PMID: 27660138 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

124 results

Results by year